Peloton Interactive Unusual Options Activity For November 25Johnson's 25 lead FGCU past Florida Tech 79-62
MIAMI (AP) — Traffic citations issued to Miami Dolphins star wide receiver Tyreek Hill after a Septemb er altercation with police have bee n dismissed after the charging officers didn’t attend a court hearing. Hill’s tickets for careless driving and failing to wear a seat belt were dismissed after the Miami-Dade Police officers failed to show up for a Monday hearing. The tickets were issued after Hill was stopped outside Hard Rock Stadium for allegedly speeding before the Dolphins’ season opener on Sept. 8. The stop escalated and an officer pulled Hill from the car, forced him to the ground and handcuffed him. Hill said in a Tuesday post on the social pl atform X, “Where all the internet cops now”. The Miami-Dade Police said the officers’ failure to appear was “an oversight” and “the matter will be handled administratively.” Still, the department defended issuing Hill the tickets. “A citation dismissed due to this reason does not indicate that the citation held no merit,” the agency said in a statement. Police body camera video from the September stop showed Hill appeared to speed past two motorcycle officers who were monitoring traffic on a road outside the stadium. They pulled over his McLaren sports car and one tapped on his window. Hill, 30, handed the officer his driver’s license, but told the officer repeatedly, “Don’t knock on my window like that.” He then put his window back up. Their verbal exchange escalated and the officers soon pulled him from the car, forcing Hill face-first to the ground. The officers cursed at Hill but he did not resist their physical force or strike at them in the video. He did tell one officer, “Don’t tell me what to do.” Hill was eventually stood up, but then an officer dragged him into a sitting position on the curb after he said a knee injury made that difficult. After about 30 minutes, Hill was issued citations and allowed to enter the stadium. One offic er was placed on administrative duty and an i nternal affairs investigation was launched. No results have been released.AP Business SummaryBrief at 6:36 p.m. ESTAlaska Permanent Capital Management to be acquired by holding company, Blue Umbrella, LLC
NoneReaching four in five online Australians with an audience of 17.185 million, News Corp Australia is the top Australian news and information publisher in the Organisation category, according to Ipsos iris October 2024 rankings released today. In the News category, News Corp Australia is the number one news and video publisher with an audience of 13.835 million and 510 million browser page views – an engaged reach of 36.87 browser page views per person. In video, the company has the largest audience for news consumption at 2.146 million, with 53 million video views for the month. News also leads across the following categories: ● Entertainment – audience of 4.594 million and 41 million page views ● Lifestyle – audience of 8.084 million and 145 million page views ● Sport – audience of 5.705 million and 60 million page views ● Travel – audience of 3.103 million and 15 million page views Managing director and publisher free news and lifestyle Pippa Leary said: “In the News category, we have an engaged reach of almost 37 page views per person which is more than 50 percent higher than our nearest competitor. Our engaged reach is stronger than ever and means better outcomes for our clients. Having a highly engaged audience who seek out our trusted brands, visit multiple pages and spend real time on our sites is critical to our success and the success of our clients.” In the News category, five of News Corp Australia’s brands feature in the top 25 sites: news.com.au with an audience of 11.132 million, and subscription led sites Herald Sun with an audience of 3.389 million, The Australian with an audience of 3.337 million, The Courier-Mail with an audience of 3.020 million and The Daily Telegraph with an audience of 2.984 million. In the Lifestyle category, News Corp Australia has the top two sites, taste.com.au with an audience of 4.483 million followed by news.com.au – Lifestyle with an audience of 3.400 million. In the Sports news category, news.com.au – Sports is number one with an audience of 3.179 million, with CODE Sports remaining in the top 10 with an audience of 1.118 million. In the Travel news category, news.com.au – Travel has an audience of 2.222 million, followed by Escape.com.au with an audience of 1.385 million, the top two sites in the category.
A new way of treating serious asthma and chronic obstructive pulmonary disease (COPD) attacks could be a “game-changer” and is the first leap in treatment for 50 years, researchers say. Offering patients an injection is more effective than the current care of steroid tablets and cuts the need for further treatment by 30%, according to a study. Benralizumab is a monoclonal antibody that targets specific white blood cells, called eosinophils, to reduce lung inflammation. It is currently used as a repeat treatment for severe asthma at a low dose, but a new clinical trial has found that a higher single dose can be very effective if injected at the time of a flare-up. The findings, published in the Lancet Respiratory Medicine, included 158 people who needed medical attention in A&E for their asthma or COPD attack (COPD is a group of lung conditions that cause breathing difficulties). Patients were given a quick blood test to see what type of attack they were having, with those suffering an “eosinophilic exacerbation” involving eosinophils (a type of white blood cell) being suitable for treatment. Around 50% of asthma attacks are eosinophilic exacerbations, as are 30% of COPD ones, according to the scientists. The clinical trial, led by King’s College London and carried out at Oxford University Hospitals NHS Foundation Trust and Guy’s and St Thomas’ NHS Foundation Trust, saw patients randomly split into three groups. One group received the benralizumab injection and dummy tablets, another received standard care (prednisolone steroids 30mg daily for five days) and a dummy injection, and the third group received both the benralizumab injection and steroids. After 28 days, respiratory symptoms of cough, wheeze, breathlessness and sputum were found to be better in people on benralizumab. And after 90 days, there were four times fewer people in the benralizumab group who failed treatment compared with those receiving steroids. Treatment with the benralizumab injection also took longer to fail, meaning fewer visits to a GP or hospital for patients, researchers said. Furthermore, people also reported a better quality of life on the new regime. Scientists at King’s said steroids can have severe side-effects such as increasing the risk of diabetes and osteoporosis, meaning switching to benralizumab could provide huge benefits. Lead investigator Professor Mona Bafadhel, from King’s, said: “This could be a game-changer for people with asthma and COPD. “Treatment for asthma and COPD exacerbations have not changed in 50 years, despite causing 3.8 million deaths worldwide a year combined. “Benralizumab is a safe and effective drug already used to manage severe asthma. “We’ve used the drug in a different way – at the point of an exacerbation – to show that it’s more effective than steroid tablets, which is the only treatment currently available.” Researchers said benralizumab could also potentially be administered safely at home or in a GP practice, as well as in A&E. First author Dr Sanjay Ramakrishnan, clinical senior lecturer at the University of Western Australia, said: “Our study shows massive promise for asthma and COPD treatment. “COPD is the third leading cause of death worldwide but treatment for the condition is stuck in the 20th century. “We need to provide these patients with life-saving options before their time runs out.” Dr Samantha Walker, director of research and innovation at Asthma and Lung UK, welcomed the findings but said: “It’s appalling that this is the first new treatment for those suffering from asthma and COPD attacks in 50 years, indicating how desperately underfunded lung health research is.” AstraZeneca provided the drug for the study and funded the research, but had no input into trial design, delivery, analysis or interpretation.
Slot glad to end Liverpool's 15-year Madrid 'pain'Thomas scores 25 as Austin Peay defeats Georgia State 62-50
AP Business SummaryBrief at 6:36 p.m. EST